Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

Blood

Volumn 120, Issue 7, 2012, Pages 1473-1484

  Lo, Miao Chia ^a   Peterson, Luke F ^b   Yan, Ming ^a   Cong, Xiuli ^a   Jin, Fulai ^c   Shia, Wei Jong ^a   Matsuura, Shinobu ^a   Ahn, Eun Young ^a   Komeno, Yukiko ^a   Ly, Minh ^d   Ommen, Hans B ^e   Chen, I Ming ^f   Hokland, Peter ^e   Willman, Cheryl L ^f   Ren, Bing ^c   Zhang, Dong Er ^a,d,g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; JANUS KINASE; STAT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA FINGERPRINTING; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84865217234     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-395335     Document Type: Article

References (50)

1. Rowley JD. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet. 1973;16(2):109-112.
2. Groupe Français de Cytogénétique Hématologique. Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet. 1990; 44(2): 169-179.
3. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88(23): 10431-10434. (Pubitemid 21915849)
4. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80(7):1825-1831.
5. Nisson PE, Watkins PC, Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet. 1992;63(2):81-88.
6. Miyoshi H, Kozu T, Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 1993;12(7):2715-2721. (Pubitemid 23218321)
7. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet. 1997;15(3):303-306. (Pubitemid 27098728)
8. Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91(9):3134-3143. (Pubitemid 28193861)
9. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 1998;95(18): 10860-10865. (Pubitemid 28413159)
10. Lutterbach B, Westendorf JJ, Linggi B, et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol. 1998;18(12):7176-7184. (Pubitemid 28533037)
11. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A. 1996;93(24):14059-14064. (Pubitemid 26424245)
12. Peterson LF, Yan M, Zhang DE. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood. 2007;109(10):4392-4398. (Pubitemid 46743408)
13. Wang L, Gural A, Sun XJ, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science. 2011;333(6043):765- 769.
14. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol. 2001;21(16):5577-5590. (Pubitemid 32702461)
15. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1- ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002; 99(1):15-23.
16. de Guzman CG, Warren AJ, Zhang Z, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol. 2002;22(15):5506-5517. (Pubitemid 34755760)
17. Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A. 2001;98(18):10398-10403. (Pubitemid 32803031)
18. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1(1):63-74. (Pubitemid 41039177)
19. Yan M, Burel SA, Peterson LF, et al. Deletion of an AML1-ETO C-terminal NcoR/SMRTinteracting region strongly induces leukemia development. Proc Natl Acad Sci U S A. 2004; 101(49):17186-17191. (Pubitemid 39627795)
20. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med. 2006;12(8):945-949. (Pubitemid 44175147)
21. Penninger JM, Irie-Sasaki J, Sasaki T, Oliveira-dos-Santos AJ. CD45: new jobs for an old acquaintance. Nat Immunol. 2001;2(5):389- 396.
22. Irie-Sasaki J, Sasaki T, Matsumoto W, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature. 2001; 409(6818):349-354. (Pubitemid 32151240)
23. Suh HS, Kim MO, Lee SC. Inhibition of granulocyte-macrophage colony-stimulating factor signaling and microglial proliferation by anti- CD45RO: role of Hck tyrosine kinase and phosphatidylinositol 3-kinase/Akt. J Immunol. 2005; 174(5):2712-2719. (Pubitemid 40279686)
24. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185- 193.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc. Series B-Methodological. 1995;57(1):289-300.
26. Li Z, Van CS, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003;100(14):8164-8169. (Pubitemid 36842516)
27. Peterson LF, Wang Y, Lo MC, Yan M, Kanbe E, Zhang DE. The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia. 2007;21(9):2010- 2019.
28. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol. 2007;9(7):804-812. (Pubitemid 47019467)
29. Yan M, Ahn EY, Hiebert SW, Zhang DE. RUNX1/ AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1- ETO9a leukemogenesis. Blood. 2009;113(4):883- 886.
30. Alcalay M, Meani N, Gelmetti V, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 2003;112(11):1751-1761. (Pubitemid 38063733)
31. Tonks A, Pearn L, Musson M, et al. Transcriptional dysregulation mediated by RUNX1- RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia. 2007; 21(12):2495-2505. (Pubitemid 350148893)
32. Gardini A, Cesaroni M, Luzi L, et al. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet. 2008; 4(11):e1000275.
33. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104(12):3679-3687. (Pubitemid 39564445)
34. Lee S, Chen J, Zhou G, et al. Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006;103(4):1030-1035. (Pubitemid 43212216)
35. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23(24):4255- 4262.
36. Wei H, Liu X, Xiong X, et al. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain. FEBS Lett. 2008;582(15): 2167-2172.
37. Wouters BJ, Lowenberg B, Erpelinck- Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088- 3091.
38. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
39. Levine RL. JAK-mutant myeloproliferative neoplasms [published online ahead of print August 7, 2011]. Curr Top Microbiol Immunol. doi: 10.1007/82-2011-170.
40. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99(4):1364-1372. (Pubitemid 34547093)
41. Li Z, Yan J, Matheny CJ, et al. Energetic contribution of residues in the Runx1 Runt domain to DNA binding. J Biol Chem. 2003;278(35):33088- 33096.
42. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16): 1617-1628. (Pubitemid 38528701)
43. Miyamoto T, Weissman IL, Akashi K. AML1/ETOexpressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A. 2000; 97(13):7521-7526. (Pubitemid 30431496)
44. Götze KS, Schiemann M, Marz S, et al. CD133- enriched CD34(-) (CD33/CD38/CD71)(-) cord blood cells acquire CD34 prior to cell division and hematopoietic activity is exclusively associated with CD34 expression. Exp Hematol. 2007;35(9): 1408-1414.
45. Kwok C, Zeisig BB, Qiu J, Dong S, So CW. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S A. 2009;106(8):2853-2858.
46. Cheng PY, Kagawa N, Takahashi Y,Waterman MR. Three zinc finger nuclear proteins, Sp1, Sp3, and a ZBP-89 homologue, bind to the cyclic adenosine monophosphate-responsive sequence of the bovine adrenodoxin gene and regulate transcription. Biochemistry. 2000;39(15):4347-4357. (Pubitemid 30212650)
47. Bevilacqua A, Fiorenza MT, Mangia F. A developmentally regulated GAGA box-binding factor and Sp1 are required for transcription of the hsp70.1 gene at the onset of mouse zygotic genome activation. Development. 2000;127(7):1541- 1551. (Pubitemid 30232604)
48. Rajakumar A, Thamotharan S, Raychaudhuri N, Menon RK, Devaskar SU. Trans-activators regulating neuronal glucose transporter isoform-3 gene expression in mammalian neurons. J Biol Chem. 2004;279(25):26768-26779. (Pubitemid 38798835)
49. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/ mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008;22(4):686-707. (Pubitemid 351565618)
50. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 2008;22(4):708-722. (Pubitemid 351565619)